• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Who Responds to SSRIs in PTSD?
RESEARCH UPDATE

Who Responds to SSRIs in PTSD?

October 30, 2022
Richard Moldawsky, MD
From The Carlat Psychiatry Report
Issue Links: Editorial Information | PDF of Issue

Richard Moldawsky, MD. Dr. Moldawsky has no financial relationships with companies related to this material.

REVIEW OF: Nøhr AK et al, Psychiatry Res 2021;301:113964

STUDY TYPE: Secondary analysis of a controlled trial

SSRIs are often used in PTSD, but it is not clear that they work for all kinds of trauma. Trials of SSRIs are generally positive in women and people with a history of sexual trauma, while trials involving combat-related trauma tend to be negative. The current study aimed to better identify predictors of ­response.

The investigators recruited patients from an ongoing controlled study of 390 patients with PTSD, conducted in 13 countries including the US. Patients were treated open-label with sertraline (100–200 mg/day) or paroxetine (20–40 mg/day) over 12 weeks, these medications being the two SSRIs with FDA approval in PTSD. All patients had experienced a trauma within the past 15 years, including assault with a weapon (31%), death or harm to someone else (21%), sexual assault (13%), or combat or war-zone experience (10%). Just under half had a history of childhood trauma. Ages ranged from 18 to 75, and 62% were female. Symptoms were tracked with the Clinically Administered PTSD Scale (CAPS) along with a patient-rated scale for depression and anxiety. The investigators used a sophisticated statistical technique called growth mixture modeling to attempt to identify predictors of drug response.

The overall response rate was 58.5%, defined as a 30% reduction in the CAPS. Sertraline and paroxetine were equally effective. Sexual assault and female gender were the main predictors of response, including a childhood history of sexual assault. A longer time between the trauma and the treatment also predicted a faster and higher rate of response. Symptoms of depression and anxiety did not predict response to the SSRI. 

One limitation of the study was the exclusion of patients with active suicidality or a history of recent treatment for major depression, anxiety disorders, or substance use disorders. On the one hand, this pure sample reduces the possibility that responses were due to treatment of comorbid disorders. On the other hand, it limits the generalizability of the findings, as does the high dropout rate (40%).

CARLAT TAKE
You can expect to see better response rates to SSRIs when treating PTSD in women and in individuals with a history of sexual trauma. This study confirms that finding, which is pretty consistent across the clinical trials, and adds a little more. Depressive and anxiety symptoms did not predict response, but those with more distant traumas were more likely to respond to SSRIs.


KEYWORDS anxiety disorders ptsd research update ssris trauma
Richard Moldawsky, MD

Is Ibogaine Safe for Opioid Detox?

More from this author
www.thecarlatreport.com
Issue Date: October 30, 2022
SUBSCRIBE NOW
Table Of Contents
Does Abortion Lead to Psychiatric Issues?
The Enduring Value of Talking Therapy
Trichotillomania: Diagnosis and Treatment
Side Effects in Depression
Who Responds to SSRIs in PTSD?
CME Post-Test, Psychotherapy, TCPR, December 2022
DOWNLOAD NOW
Featured Book
  • AUDFB1e_CoilBound_Graphic2_transparent_sm.png

    (PRE-ORDER) Treating Alcohol Use Disorder—A Fact Book (2023)

    All the tools and information needed to assess and treat your patients who are struggling with...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.